IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

PHASE3CompletedINTERVENTIONAL
Enrollment

470

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Ribavirin (RBV)

24 weeks of active RBV

DRUG

BI 201335 (Faldaprevir)

16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335

DRUG

Ribavirin (RBV)

24 weeks of active RBV

DRUG

BI 207127

24 weeks of BI 207127

DRUG

BI 201335 (Faldaprevir)

24 weeks of BI 201335

DRUG

Ribavirin (RBV)

16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin

DRUG

BI 207127

16 weeks BI 207127 followed by 8 weeks placebo to BI 207127

DRUG

Faldaprevir (BI 201335)

24 weeks of 201335

DRUG

BI 207127

24 weeks of BI 207127

Trial Locations (101)

Unknown

1241.20.00026 Boehringer Ingelheim Investigational Site, Dothan

1241.20.00033 Boehringer Ingelheim Investigational Site, Chula Vista

1241.20.00006 Boehringer Ingelheim Investigational Site, La Mesa

1241.20.00003 Boehringer Ingelheim Investigational Site, Oceanside

1241.20.00008 Boehringer Ingelheim Investigational Site, Poway

1241.20.00015 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1241.20.00014 Boehringer Ingelheim Investigational Site, Ft. Pierce

1241.20.00004 Boehringer Ingelheim Investigational Site, Maitland

1241.20.00010 Boehringer Ingelheim Investigational Site, Decatur

1241.20.00001 Boehringer Ingelheim Investigational Site, New Orleans

1241.20.00018 Boehringer Ingelheim Investigational Site, Baltimore

1241.20.00002 Boehringer Ingelheim Investigational Site, Chevy Chase

1241.20.00032 Boehringer Ingelheim Investigational Site, Springfield

1241.20.00009 Boehringer Ingelheim Investigational Site, Las Vegas

1241.20.00016 Boehringer Ingelheim Investigational Site, New York

1241.20.00031 Boehringer Ingelheim Investigational Site, New York

1241.20.00019 Boehringer Ingelheim Investigational Site, Rochester

1241.20.00024 Boehringer Ingelheim Investigational Site, Tulsa

1241.20.00013 Boehringer Ingelheim Investigational Site, Portland

1241.20.00005 Boehringer Ingelheim Investigational Site, Austin

1241.20.00017 Boehringer Ingelheim Investigational Site, Dallas

1241.20.00012 Boehringer Ingelheim Investigational Site, Houston

1241.20.00022 Boehringer Ingelheim Investigational Site, Houston

1241.20.00020 Boehringer Ingelheim Investigational Site, Richmond

1241.20.43003 Boehringer Ingelheim Investigational Site, Graz

1241.20.01001 Boehringer Ingelheim Investigational Site, Vancouver

1241.20.01008 Boehringer Ingelheim Investigational Site, Vancouver

1241.20.01010 Boehringer Ingelheim Investigational Site, Vancouver

1241.20.01003 Boehringer Ingelheim Investigational Site, Victoria

1241.20.01006 Boehringer Ingelheim Investigational Site, Hamilton

1241.20.01002 Boehringer Ingelheim Investigational Site, Toronto

1241.20.01005 Boehringer Ingelheim Investigational Site, Whitby

1241.20.01007 Boehringer Ingelheim Investigational Site, Montreal

1241.20.33003 Boehringer Ingelheim Investigational Site, Clermont-Ferrand

1241.20.33004 Boehringer Ingelheim Investigational Site, Lyon

1241.20.33006 Boehringer Ingelheim Investigational Site, Marseille

1241.20.33001 Boehringer Ingelheim Investigational Site, Montpellier

1241.20.33005 Boehringer Ingelheim Investigational Site, Nice

1241.20.33007 Boehringer Ingelheim Investigational Site, Paris

1241.20.33002 Boehringer Ingelheim Investigational Site, Pessac

1241.20.33009 Boehringer Ingelheim Investigational Site, Rennes

1241.20.33008 Boehringer Ingelheim Investigational Site, Vandœuvre-lès-Nancy

1241.20.49002 Boehringer Ingelheim Investigational Site, Berlin

1241.20.49004 Boehringer Ingelheim Investigational Site, Berlin

1241.20.49012 Boehringer Ingelheim Investigational Site, Bonn

1241.20.49013 Boehringer Ingelheim Investigational Site, Cologne

1241.20.49001 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1241.20.49014 Boehringer Ingelheim Investigational Site, Hamburg

1241.20.49009 Boehringer Ingelheim Investigational Site, Herne

1241.20.49008 Boehringer Ingelheim Investigational Site, Kiel

1241.20.49011 Boehringer Ingelheim Investigational Site, Leipzig

1241.20.49006 Boehringer Ingelheim Investigational Site, Magdeburg

1241.20.49003 Boehringer Ingelheim Investigational Site, München

1241.20.49010 Boehringer Ingelheim Investigational Site, Oberhausen

1241.20.49005 Boehringer Ingelheim Investigational Site, Ulm

1241.20.49007 Boehringer Ingelheim Investigational Site, Würzburg

1241.20.36001 Boehringer Ingelheim Investigational Site, Budapest

1241.20.36002 Boehringer Ingelheim Investigational Site, Kaposvár

1241.20.35301 Boehringer Ingelheim Investigational Site, Dublin

1241.20.35302 Boehringer Ingelheim Investigational Site, Dublin

1241.20.35303 Boehringer Ingelheim Investigational Site, Dublin

1241.20.39007 Boehringer Ingelheim Investigational Site, Ancona

1241.20.39003 Boehringer Ingelheim Investigational Site, Brescia

1241.20.39002 Boehringer Ingelheim Investigational Site, Milan

1241.20.39008 Boehringer Ingelheim Investigational Site, Milan

1241.20.39006 Boehringer Ingelheim Investigational Site, Napoli

1241.20.39005 Boehringer Ingelheim Investigational Site, Pavia

1241.20.39001 Boehringer Ingelheim Investigational Site, Torino

1241.20.39004 Boehringer Ingelheim Investigational Site, Torino

1241.20.31001 Boehringer Ingelheim Investigational Site, Amsterdam

1241.20.31003 Boehringer Ingelheim Investigational Site, Amsterdam

1241.20.31004 Boehringer Ingelheim Investigational Site, Amsterdam

1241.20.31005 Boehringer Ingelheim Investigational Site, Groningen

1241.20.31006 Boehringer Ingelheim Investigational Site, The Hague

1241.20.35103 Boehringer Ingelheim Investigational Site, Aveiro

1241.20.35104 Boehringer Ingelheim Investigational Site, Coimbra

1241.20.35101 Boehringer Ingelheim Investigational Site, Lisbon

1241.20.35102 Boehringer Ingelheim Investigational Site, Porto

1241.20.35105 Boehringer Ingelheim Investigational Site, Vila Real

1241.20.40001 Boehringer Ingelheim Investigational Site, Bucharest

1241.20.40002 Boehringer Ingelheim Investigational Site, Bucharest

1241.20.40003 Boehringer Ingelheim Investigational Site, Bucharest

1241.20.70002 Boehringer Ingelheim Investigational Site, Chelyabinsk

1241.20.70001 Boehringer Ingelheim Investigational Site, Moscow

1241.20.70004 Boehringer Ingelheim Investigational Site, Saint Petersburg

1241.20.70005 Boehringer Ingelheim Investigational Site, Saint Petersburg

1241.20.34007 Boehringer Ingelheim Investigational Site, A Coruña

1241.20.34004 Boehringer Ingelheim Investigational Site, Alicante

1241.20.34002 Boehringer Ingelheim Investigational Site, Barcelona

1241.20.34005 Boehringer Ingelheim Investigational Site, Barcelona

1241.20.34003 Boehringer Ingelheim Investigational Site, Madrid

1241.20.34001 Boehringer Ingelheim Investigational Site, Majadahonda, Madrid

1241.20.34008 Boehringer Ingelheim Investigational Site, Santander

1241.20.34006 Boehringer Ingelheim Investigational Site, Valencia

1241.20.44005 Boehringer Ingelheim Investigational Site, Bristol

1241.20.44007 Boehringer Ingelheim Investigational Site, Liverpool

1241.20.44001 Boehringer Ingelheim Investigational Site, London

1241.20.44002 Boehringer Ingelheim Investigational Site, London

1241.20.44006 Boehringer Ingelheim Investigational Site, London

1241.20.44004 Boehringer Ingelheim Investigational Site, Nottingham

1241.20.44003 Boehringer Ingelheim Investigational Site, Southampton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01732796 - IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 | Biotech Hunter | Biotech Hunter